Examining Current & Potential Targets for Treating EGFR-Mutated Non-Small Cell Lung Cancer
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Studies provide evidence of potential efficacy for a novel CDK4-selective inhibitor and long-lasting benefits for a pan-AKT inhibitor
The International Journal of Cancer is a cancer journal from the Union for International Cancer Control covering experimental and clinical cancer research.
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the…
Anthony M. Hunter, MD, discusses the evolution of myelofibrosis treatment beyond JAK inhibitors.
During an OncLive Peer Exchange, a panel of expert clinicians in CRC discussed studies seeking to further define the role of MRD testing in CRC.
First-line treatment with the combination of Versamune HPV and pembrolizumab met a best overall response end point in recurrent/metastatic HNSCC.
ESMO is Europe’s leading medical oncology society, providing a professional network for its members and working with national societies across Europe.
Mohamad Mohty, MD, PhD, highlights key takeaways from the 50th Annual EMBT Meeting, focusing on ongoing efforts within the GVHD treatment arena.
David J. Andorsky, MD, discussed real-world findings from a study which evaluated BTK inhibitors in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
A Roswell Park-led team uncovers beneficial effects of combining VEGFR-targeting TKIs with checkpoint inhibitors in new research.